Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)

NCT03671460 is registered in ClinicalTrials.gov with Tianjin Mycure Medical Technology Co., Ltd as lead sponsor.

NCT NCT03671460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)
Lead sponsor
Tianjin Mycure Medical Technology Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
September 7, 2018
Completion date
January 1, 2021
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia